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d Cx46-mediated cell-cell communication is essential for GBM
self-renewal
d A communication-based screening platform identifies
clofazimine as a Cx46 inhibitor
d Clofazimine targets CSCs and has little effect on non-stem
tumor cells
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Cx46 was previously shown to be
essential for glioblastoma cancer stem
cell maintenance. Here, Mulkearns-
Hubert et al. show that cancer stem cells
depend on Cx46-mediated cell-cell
communication and identify a Cx46
inhibitor, clofazimine. Clofazimine
preferentially inhibits Cx46-mediated
communication and targets cancer stem
cells to decrease tumor growth.
Mulkearns-Hubert et al., 2019, Cell Reports 27, 1062–1072
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Gap-junction-mediated cell-cell communication en-
ables tumor cells to synchronize complex processes.
We previously found that glioblastoma cancer stem
cells (CSCs) express higher levels of the gap junction
protein Cx46 compared to non-stem tumor cells
(non-CSCs) and that this was necessary and suffi-
cient for CSCmaintenance. To understand themech-
anism underlying this requirement, we use point mu-
tants to disrupt specific functions of Cx46 and find
that Cx46-mediated gap-junction coupling is critical
for CSCs. To develop a Cx46 targeting strategy, we
screen a clinically relevant small molecule library
and identify clofazimine as an inhibitor of Cx46-spe-
cific cell-cell communication. Clofazimine attenuates
proliferation, self-renewal, and tumor growth and
synergizes with temozolomide to induce apoptosis.
Although clofazimine does not cross the blood-brain
barrier, the combination of clofazimine derivatives
optimized for brain penetrance with standard-of-
care therapies may target glioblastoma CSCs.
Furthermore, these results demonstrate the impor-
tance of targeting cell-cell communication as an
anti-cancer therapy.
INTRODUCTION
Glioblastoma (GBM; grade IV astrocytoma), the most commonly
occurring primary malignant brain tumor, remains uniformly fatal
despite aggressive therapy that includes surgery, radiation, and
chemotherapy. Increased understanding of the molecular alter-
ations underlying tumorigenesis has not translated to clinical
success; patient prognosis remains poor, with a median survival
of only 14–16 months and 5-year survival rates of less than 3%
(McGirt et al., 2009; Stupp et al., 2009, 2015). One factor under-
lying the difficulty in treating GBM is the cellular diversity present
within these tumors. Heterogeneous populations of cancer stem
cells (CSCs) exhibit essential characteristics of sustained self-
renewal, persistent proliferation, and ability to initiate tumors
when transplanted intomice (Lathia et al., 2015), and they display
resistance to the GBM standard-of-care therapies: radiation and
temozolomide (Baoet al., 2006;Chenet al., 2012; Liu et al., 2006).
Efforts to treat GBM are focused on the ability to target CSCs,
because thismay lead to the development ofmore effective ther-
apies for GBM with increased clinical success.
Cell-cell communication is mediated through the connexin
family of proteins and the gap junction (GJ) channels that these
proteins comprise. Six connexin proteins assemble into a chan-
nel through the plasmamembrane that can exchange small mol-
ecules between the cytoplasm and the extracellular space as
hemichannels. When these channels dock with a compatible
hexamer on a neighboring cell, a GJ is formed. GJ intercellular
communication (GJIC) exchanges ions, microRNAs (miRNAs),
small metabolites such as glucose, antioxidants, and peptides
between cells, allowing them to coordinate their phenotypes
and respond to environmental conditions (Goodenough and
Paul, 2009). Connexin proteins serve three main cellular func-
tions: exchange of small molecules between cells as GJs, ex-
change of small molecules between a cell and the extracellular
space as hemichannels, and binding to intracellular proteins
(Goodenough and Paul, 2003, 2009; Leithe et al., 2018; Stout
et al., 2004).
Previous work based mainly on connexin 43 (Cx43) suggested
that connexins act as tumor suppressors (Aasen et al., 2016).
However, we have identified pro-tumorigenic connexins in pros-
tate cancer (Zhang et al., 2015), breast cancer (Thiagarajan et al.,
2018), leukemia (Sinyuk et al., 2015), and GBM (Hitomi et al.,
2015). GBM CSCs express higher levels of Cx46 compared to
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non-CSCs, and Cx46 is required for CSC proliferation, survival,
self-renewal, and tumor formation (Hitomi et al., 2015). Pan-GJ
inhibitors slowed tumor growth in mice with intracranial tumors,
but these compounds inhibit connexins as an off-target effect.
Therefore, these compounds would likely cause side effects in
patients based on their broad effects targeting multiple connex-
ins that play essential roles in many normal organs.
Here, we usedmutational analysis and identified the dominant
function of Cx46 in GBM CSCs to be cell-cell communication
throughGJs (GJIC) rather than hemichannel activity. We thus hy-
pothesized that targeting of CSCs through specific inhibition of
Cx46 would slow tumor growth and lead to the development of
new therapies for patients with GBM. A screen of U.S. Food
and Drug Administration (FDA)-approved small molecules iden-
tified the anti-leprosy drug clofazimine as a preferential inhibitor
of Cx46-mediated cell-cell communication and GBMCSCmain-
tenance. Because clofazimine was unable to penetrate the
































































































































































































Figure 1. Mutational Analysis Indicates that
Cell-Cell Communication Is Essential to
Maintain Glioblastoma Cancer Stem Cells
(A) Schematic showing the location of introduced
Cx46 point mutants in the protein.
(B) CSCs from the patient-derived xenograft spec-
imen T4121 were transfected with wild-type or
mutant Cx46, and the number of cellswasmeasured
at the indicated times after plating using CellTiter-
Glo. The values shown are relative to day 0. n = 4
experiments performed in triplicate. *p < 0.05, **p <
0.01, ***p < 0.001 by two-way ANOVA compared to
vector to test for significant differences between the
curves.
(C and D) Transfected CSCs from the PDX speci-
mens T4121 (C) and T387 (D) were assessed for
active caspase-3/7 on day 1 using Caspase-Glo.
The values shown are normalized to the CellTiter-
Glo signal at day 1 and are given relative to vector.
n = 4 experiments for T4121 and n = 3 for T387, all
performed in triplicate. *p < 0.05, **p < 0.01, ***p <
0.001 by Student’s unpaired t test with Welch’s
correction compared to vector.
(E andF) TransfectedCSCs from thepatient-derived
xenograft specimens T4121 (E) and T387 (F) were
plated in a limiting-dilution format (between 1 and 20
cells/well of a 96-well plate), and the number of
spheres per well was counted between days 10 and
14. The stem cell frequency was calculated using
the online algorithmdescribed in the STARMethods
section. The values shown are relative to the stem
cell frequency of the vector-transfected cells. n = 3
experiments, with 24 technical replicates per cell
number per experiment. *p < 0.05, **p < 0.01, ***p <
0.001 by c2 test compared to the vector control.
Data are represented as mean ± SEM for (B)–(D)
and mean ± range for (E) and (F).
See also Figure S1.
future derivatization of the compound is
required to permeate the blood-brain bar-
rier and may produce an optimal targeting
drug for GBM CSCs. Altogether, our data
suggest that repurposing and derivatization of this and similar
compounds may benefit patients with GBM.
RESULTS
Cx46-Mediated Cell-Cell Communication Is Essential to
Maintain GBM CSCs
Our previous studies identified Cx46 as a potential anti-CSC
target (Hitomi et al., 2015). To develop a strategy to specifically
inhibit Cx46, we first sought to determine the function of Cx46
required to maintain GBM CSC properties. To achieve this, we
identified a panel of Cx46 mutations that would allow us to
deduce the individual importance of GJIC and hemichannel ac-
tivity. Two Cx46 point mutations have been reported in human
patients with cataracts (Hansen et al., 2006; Santhiya et al.,
2010). These mutations, L11S and T19M, are both located in
the N-terminal tail of the Cx46 protein (Figure 1A) and have
been functionally investigated in the context of the rat protein
Cell Reports 27, 1062–1072, April 23, 2019 1063
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Figure 2. A Screen of FDA-Approved Small Molecules Identifies Clofazimine as an Inhibitor of Cx46-Mediated Cell-Cell Communication
(A) Schematic of calcein dye transfer between HeLa cells expressing no exogenous connexin proteins and HeLa cells expressing Cx43 or Cx46. Cells are labeled
with Vybrant DiD (pseudocolored magenta), which cannot pass between cells, and calcein red-orange AM (pseudocolored black), which spreads between cells
through gap junctions.
(B) Parachute dye transfer assay of parental HeLa cells, stable Cx46-expressing HeLa cells, and transiently transfected Cx43-expressing HeLa cells. Unlabeled
recipient cells were plated in a subconfluent monolayer, and dual-labeled cells were added. If gap junctions formed between labeled and unlabeled cells, the
calcein dye (shown in black) diffused into cells that were not labeled with DiD (magenta). Scale bar, 50 mm.
(C) Schematic of the parachute dye transfer assay with timing used to test the NIH Clinical Collection compounds for inhibition of Cx46-mediated cell-cell
communication in stable HeLa-Cx46 cells. A subconfluent monolayer of HeLa-Cx46 cells was plated and incubated with drugs at 10 mM for 3 h. A separate
population was labeled with calcein AM and Vybrant DiD and added to the recipients, and dye transfer was imaged for 5 h.
(legend continued on next page)
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in Xenopus oocytes (Tong et al., 2013, 2015). When co-ex-
pressed with wild-type Cx46, the presence of the L11S mutation
was shown to dramatically reduce both GJIC and hemichannel
activity (Tong et al., 2013). In contrast, while expression of
Cx46 T19M alone was not sufficient for GJIC, co-expression of
the Cx46 T19M mutant with wild-type Cx46 increased hemi-
channel activity but did not affect GJIC (Tong et al., 2015). We
also used a cysless mutant previously engineered in Cx43 that
disrupts the three disulfide bonds necessary to maintain the
structure of connexins required for GJ docking. This mutant
was reported to block GJIC without affecting hemichannel activ-
ity of Cx43 in both Xenopus oocytes and ovarian granulosa cells
(Bao et al., 2004; Tong et al., 2007), and we confirmed its inhibi-
tion of GJIC in HeLa cells (data not shown).
We introduced these mutations into human Cx46 cDNA and
transfected the DNA into GBM CSCs isolated from two
patient-derived xenografts (PDXs; T4121 and T387). Using
qPCR, we were able to detect the expression of each Cx46
mutant in CSCs at the mRNA level (Figures S1A and S1B).
Expression of Cx46 T19M or overexpression of wild-type
Cx46 in the presence of endogenous Cx46 had little effect on
CSC proliferation (Figure 1B; Figure S1C), apoptosis (Figures
1C and 1D), or self-renewal (Figures 1E and 1F), a hallmark
of the CSC state, which was assessed by limiting dilution
sphere-formation analysis, while we observed small but signifi-
cant decreases in proliferation and self-renewal with expression
of Cx46 L11S. However, expression of Cx46 cysless dramati-
cally decreased CSC proliferation, increased apoptosis, and
decreased self-renewal in both patient-derived specimens.
Expression of these mutants in non-CSCs, which express low
levels of Cx46 (Hitomi et al., 2015), had little effect beyond
that of expressing wild-type Cx46 (Figures S1D–S1G). Alto-
gether, these observations demonstrate that when expressed
with endogenous Cx46, the cysless mutant, which has been
shown to have the greatest effect on cell-cell communication,
also had the greatest effect on CSC maintenance compared
to the other mutants (Table S1) and led us to conclude that
GJIC mediated by Cx46 is essential to maintain GBM CSC pro-
liferation, survival, and self-renewal.
A Screen of FDA-Approved Small Molecules Identifies
Clofazimine as an Inhibitor of Cx46-Mediated GJIC
Based on our observation that GBM CSCs require Cx46-medi-
ated GJIC for survival, we designed an assay system to screen
for inhibitors of this process.We assessed GJIC using a quantita-
tive calcein transfer assay (Figure 2A) (Hitomi et al., 2015), amodi-
fication of the parachute dye-uptake assay (Ziambaras et al.,
1998). In this assay, cells labeled with both a GJ-permeable
dye (calcein red-orange acetoxymethyl [AM], shown in black)
and a non-spreading membrane dye (1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt
[DiD], shown in magenta) were added to a subconfluent mono-
layer of unlabeled cells. The formation of GJs is indicated by
membrane dye-negative cells that become calcein positive with
time. HeLa cells express low levels of endogenous connexins (Elf-
gang et al., 1995) and display minimal dye coupling (Figure 2B;
Figure S2). However, stable expression of Cx46 or transient
expression of Cx43 in HeLa cells established functional GJs
and coupling between cells, as evidenced by the spread of cal-
cein dye (shown in black) between cells (Figure 2B; Figure S2).
Using stable Cx46-expressing HeLa cells, we then screened
the 727 compounds of the NIH Clinical Collection of FDA-
approved small molecules for their ability to inhibit Cx46-medi-
ated GJIC at a concentration of 10 mM over a treatment time of
3 h (Figure 2C). The spread of calcein between treated cells
was imaged and compared to both vehicle (DMSO) treatment
and treatment with the pan-GJ inhibitor carbenoxolone (CBX;
200 nM). We identified several compounds that blocked Cx46-
mediated GJIC compared to CBX as a positive control (Fig-
ure 2D). Several of the top hits were screened at concentrations
between 0.1 and 10 mM, and we found that the FDA-approved
anti-mycobacterial drug clofazimine inhibited Cx46 GJIC at
the lowest concentrations compared to the other hits (Fig-
ure 2E), with little effect on Cx46 hemichannel activity, as deter-
mined by the amount of calcein lost from sparsely plated cells
(Figure 2F). Altogether, these results demonstrate that clofazi-
mine is a candidate to inhibit Cx46 GJIC without affecting hemi-
channel activity.
Cx46 Is More Sensitive Than Other Connexins
Expressed in GBM to Inhibition by Clofazimine
To specifically target Cx46 in CSCs, the lead compound should
have limited efficacy against the 20 other human connexins. To
test the specificity of clofazimine for Cx46, we first screened
for the additional connexins expressed in GBM using bioinfor-
matics. Using both RNA sequencing and microarray data from
the GlioVis database (http://gliovis.bioinfo.cnio.es/) (Bowman
et al., 2017), we identified the connexins most highly expressed
in GBM compared to normal brain (Figure 3A). In addition to
Cx46, which was the most highly expressed relative to normal
brain tissue, Cx45 and Cx37 were detected at higher levels in
GBM. We also screened clofazimine against Cx43, the most
ubiquitously expressed connexin throughout the body (Oya-
mada et al., 2005). HeLa cells expressing any of these four
connexins displayed GJ coupling, as evidenced by the spread
of calcein dye (black) from DiD (magenta)-labeled donor cells
to unlabeled recipient cells (Figure 3B). As expected, the pan-
GJ inhibitor CBX inhibited calcein spread mediated by each
connexin. However, while coupling of HeLa cells expressing
Cx46 was blocked by clofazimine, cells expressing Cx43,
(D) Summary graph of the degree to which the drugs from the NIH Clinical Collection inhibited Cx46-mediated GJIC. Percent inhibition is relative to DMSO vehicle
control treatment (0%) and the pan-gap-junction inhibitor CBX (100%).
(E and F) Validation of the screen results. Cells were treated with increasing concentrations (0.1, 1, and 10 mM) of the top four hits from the screen and one hit that
did not show inhibition (purple). Those cells were then either plated and incubated with a labeled population of donor cells (E) to measure GJIC or plated sparsely
(F) to assay dye leakage through hemichannels. 0 on the plot in (E) indicates no inhibition was observed. Data are normalized to DMSO (0% inhibition) and CBX
(100%), and these experiments were performed in triplicate.
See also Figure S2.
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Cx37, and Cx45 continued to exhibit GJIC even in the presence
of clofazimine (Figure 3C). These data indicate that of the con-
nexins tested, Cx46-mediated GJIC was specifically inhibited
by clofazimine.
Clofazimine Preferentially Targets GBM CSCs
Compared to Non-CSCs
Our previous studies identified Cx46 as an essential connexin
expressed by GBM CSCs, and our preceding results indicated
that clofazimine preferentially inhibits coupling of cells ex-
pressing Cx46. Based on these results, we hypothesized that
clofazimine would specifically target GBM CSCs compared to
non-CSCs. Treatment of CSCs and non-CSCs with increasing
concentrations of clofazimine from 0.05 to 5 mM allowed
us to calculate half maximal inhibitory concentration (IC50)
values of approximately 2 mM for the CSC population of four
PDX specimens (Figure 4A). In contrast, the non-CSC popula-
tions did not reach 50% growth inhibition within the same con-
centration range of clofazimine (Figure 4A; Figure S3A). For
comparison, the IC50 value of the immortalized, non-trans-
formed fibroblast cell line NIH 3T3 was calculated to be
approximately 86 mM, indicating that CSCs were dramatically
more sensitive than other cell types to clofazimine. Limiting
dilution analysis showed a significant and striking inhibitory
effect of clofazimine on CSC self-renewal, even at a concentra-
tion at which proliferation was only minimally affected (0.5 mM)
(Figure 4B; Figure S3A). This inhibition of CSC growth and self-
renewal was accompanied by a concentration-dependent
increase in apoptosis in the CSC population, with minimal in-
duction of apoptosis in the non-CSCs (Figure 4C).
Based on our data that clofazimine inhibited dye coupling in
HeLa cells expressing Cx46, but not other connexins (Figures
3B and 3C), we hypothesized that clofazimine was similarly
acting through an inhibition of GJIC in CSCs. Treatment with clo-
fazimine inhibited the spread of the fluorescent glucose analog
2-NBDGmicroinjected in CSCs compared to vehicle (Figure 4D),
confirming that clofazimine is able to inhibit GJIC in CSCs. To
test whether clofazimine induced additional off-target effects,
we performed RNA sequencing on CSCs from xenograft spec-
imen T4121 treated with 2 mM clofazimine for a short period of
6 h. Increases and decreases in transcript expression with treat-
ment compared to vehicle were relatively modest, with changes
falling within 3-fold of the value of the vehicle-treated samples
(Figures S3B and S3C). We performed functional gene annota-
tion and pathway enrichment analysis on the top differentially
expressed genes (https://david.ncifcrf.gov/) and found no signif-
icant pathway enrichment within reported gene groups, suggest-
ing limited off-target effects with clofazimine treatment. Clofazi-
mine has also been reported to target GBM cells by affecting the
function of the membrane potassium channel Kv1.3, which is
highly expressed in many cancer cell lines compared to normal
tissue (Leanza et al., 2015; Venturini et al., 2017). We therefore
tested CSCs and non-CSCs to determine whether higher levels
of Kv1.3 in the CSCs could be responsible for their sensitivity
to clofazimine. However, GBMCSCs from the PDX T4121, which
are more sensitive to clofazimine than their non-CSC counter-
parts, expressed approximately 4-fold less Kv1.3 transcript
than non-CSCs (Figure S3D), suggesting that the enhanced




Figure 3. Cx46 Is More Sensitive Than Other
Connexins Expressed in GBM to Inhibition
by Clofazimine
(A) Heatmap of connexin mRNA expression in GBM
compared to normal brain tissue by both RNA
sequencing and microarray. Data are from The
Cancer Genome Atlas (TCGA) and were obtained
from GlioVis. Red indicates higher expression
compared to normal brain, while blue indicates
lower expression than normal brain tissue.
(B) Parachute dye transfer assay of HeLa cells ex-
pressing different connexin proteins. HeLa cells
were transfected with connexin proteins, unlabeled
cells were plated in a subconfluent monolayer, and
cells dual labeled with Vybrant DiD (shown in
magenta) and calcein red-orange AM (shown in
black) were treated with DMSO, 1 mM clofazimine
(CFZ), or 200 mM carbenoxolone (CBX) for 3 h and
added to the unlabeled cells. The presence of cal-
cein dye (black) in cells that are not magenta in-
dicates GJIC. Scale bar, 50 mm.
(C) Quantification of (B). The percent inhibition of
GJIC with clofazimine is shown compared to that of
vehicle and the pan-gap-junction inhibitor CBX.
***p < 0.001 by unpaired Student’s t test with
Welch’s correction compared to the DMSO-treated
control. Data are represented as mean ± SEM. n = 3.
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Inhibition of GJs has been reported to increase the cellular
levels of reactive oxygen species (ROS) (Giardina et al., 2007;
Le et al., 2014; Z€undorf et al., 2007). As expected, treatment
with 1 mMclofazimine for 3 days led to an increase in intracellular
ROS, as measured by production of fluorescent 20,70-dichloro-
fluorescein (DCF) from 20,70-dichlorodihydrofluorescein diace-
tate (H2DCFDA) and detected using flow cytometry (Figure 4E).
Based on our observations that clofazimine is toxic to GBM
CSCs, we combined clofazimine with temozolomide, the GBM
standard-of-care chemotherapy. Temozolomide alone (50 mM)
did not increase ROS compared to DMSO vehicle treatment,
but a combination of temozolomide with clofazimine increased
ROS above the level observed for clofazimine alone (Figure 4E).
This increase in ROSwas accompanied by a significant increase
in apoptosis in cells treated with both temozolomide and clofazi-
mine compared to either compound alone (Figure 4F), and this
increase with the combination treatment was greater than an
additive effect, suggesting that clofazimine sensitizes CSCs to
chemotherapy. Altogether, these results indicate that clofazi-
mine inhibits GBM CSC growth, survival, and self-renewal, likely
through its effects on Cx46-mediated GJIC, and combines with





Figure 4. Clofazimine Preferentially Targets
GBM CSCs Compared to Non-CSCs
(A) Summary of IC50 values for clofazimine (CFZ) in
four patient-derived xenograft matched CSCs and
non-CSCs and the NIH 3T3 untransformed fibro-
blast cell line. Cells were treated with increasing
concentrations of clofazimine for 3 days, and cell
number was measured using CellTiter-Glo. n = at
least 3 experiments with cells plated in triplicate.
Data are represented as the mean.
(B) CSCs were plated into drug-containing medium
at increasing cell densities (1, 5, 10, and 20 cells/
well of a 96-well plate), and the number of wells
containing spheres was counted after 10–14 days.
The online algorithm described in the STAR
Methods section was used to calculate stem cell
frequency. ***p < 0.001 by c2 test compared to the
DMSO-treated control. Data are represented as
mean ± range. n = 3 experiments, with 24 technical
replicates per cell number per experiment.
(C) CSCs and non-CSCs were treated with clofazi-
mine for 3 days, and active caspase-3/7 was
measured using Caspase-Glo. The values shown
are normalized to the number of total cells at the
same timepoint andare relative to theDMSOcontrol
for each cell type. *p < 0.05, **p < 0.01, ***p < 0.001
by unpaired Student’s t test with Welch’s correction
compared to the respective DMSO-treated control.
Data are represented as mean ± SEM. n = 4 exper-
iments, each performed in triplicate.
(D) CSCs were plated in a subconfluent monolayer
on Geltrex, treated with 2 mM clofazimine for 16 h,
and microinjected with 2-NBDG (pseudocolored
black) and a far-red fluorescently labeled immuno-
globulin G (IgG) (pseudocolored magenta). Cells
were imaged over 2 h, and the number of cells
receiving 2-NBDG from each donor cell was quan-
tified. *p < 0.05 by unpaired Student’s t test with
Welch’s correction compared to theDMSO-treated
control. Data are represented asmean ±SEM. n = 8
donors over 7 fields (DMSO) and n=4donors over 2
fields (clofazimine). Scale bar, 50 mm.
(E) Flowcytometrywas used tomeasure the amount
of fluorescent DCF produced from H2DCFDA as a
measurement of ROS. CSCs were treated concur-
rently for 24 h with 50 mM temozolomide (TMZ) and
for 16hwith 1mMclofazimine,manually removed fromtheplateusingacell scraper,andsubjected toflowcytometry.Representativedata from1ofn=3experiments
are shown.
(F) Cells were plated in 96-well plates and treated as in (E). Active caspase-3/7 was measured using Caspase-Glo. Data are normalized to the total number of
cells at that time and are shown relative to the DMSO-treated control. *p < 0.05, ***p < 0.001 by two-way ANOVA with multiple comparisons compared to
treatment with clofazimine alone. Data are represented as mean ± SEM. n = 4 experiments, each performed in triplicate.
See also Figure S3.
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Clofazimine Decreases Tumor Growth In Vivo
Clofazimine is generally well tolerated in patients; a 19-year
retrospective study of patients receiving multi-drug therapy for
leprosy reported no adverse effects of clofazimine when given
at the recommended dosage (Nair, 2018). Minor side effects
include gastrointestinal intolerance and skin pigmentation; how-
ever, rare cases of cardiotoxicity have been observed (Choudhri
et al., 1995). The current World Health Organization (WHO)
dosing schedule of clofazimine for multibacillary leprosy in-
cludes one monthly dose of 300 mg and an additional 50 mg
daily in combination with the drugs dapsone and rifampicin for
a period of 12 months (Fischer, 2017).
To determine whether clofazimine inhibits tumor growth
in vivo, we selected a dosage equivalent to the maximum rec-
ommended daily human dose (FDA, 2016), 200 mg/day
(2.44 mg/kg based on an average human body weight of
80 kg), solubilized in corn oil. At this dose, the brains of animals
treated intraperitoneally for 2 weeks contained less than 0.1 ng
of clofazimine per milliliter of brain homogenate (Figure 5A).
Even when animals were treated with the supraphysiological
dose of 4.88 mg/kg for 2 weeks, the concentration of clofazi-
mine in the brain (0.55 ng/mL) was almost 2,000-fold less
than the calculated IC50 for CSCs in vitro. We also observed
low penetration of the blood-brain barrier by clofazimine in
mice microscopically (Figure S4A). Based on this low brain
penetration by clofazimine, rather than treating mice with intra-
cranial tumors, we instead treated animals bearing subcutane-
ous flank tumors generated by implantation of CSCs from
the PDX specimen T4121. Clofazimine administration began
once all animals presented palpable tumors. Treatment with
clofazimine at 2.44 mg/kg by intratumoral injection led to a
significant decrease in tumor growth over time (Figure 5B)
and a decrease in final tumor size (Figure 5C). A similar effect
was observed when animals were treated intraperitoneally
with clofazimine (Figure S4B). Because the normal tissue
distribution of Cx46 is primarily in the lens, we also tested
whether inhibition of Cx46 had an effect on animal vision and
observed no significant changes compared to treatment with
vehicle (Figure S4C). Altogether, our results indicate that clofa-
zimine targeting of Cx46-mediated GJIC is able to slow tumor
growth without affecting other major Cx46 functions, including
vision.
DISCUSSION
Connexin proteins serve three main cellular functions: ex-
change of small molecules between cells, exchange of small
molecules between cells and the extracellular space, and medi-
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Figure 5. Clofazimine Decreases Tumor Growth In Vivo
(A) Male and female (n = 4 each) NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice
were treated with clofazimine (CFZ) at 2.44 or 4.88 mg/kg in 200 mL of corn oil
by intraperitoneal (IP) injection daily for 2 weeks under a treatment plan of
5 days on, 2 days off, and 5 days on the treatment. On day 12, animals were
euthanized, and brains were homogenized in PBS and subjected to mass
spectrometry for clofazimine. Data are shown as mean ± SEM.
(B and C) Male NSG mice (n = 4 per arm) were injected with 5 3 105 T4121
CSCs into their right flanks. Four weeks later, when tumors became palpable,
animals were treated daily with clofazimine at 2.44 mg/kg in 10 mL of corn oil
injected directly into the tumor for 8 days. Tumor size was measured using
digital calipers, and the change in tumor volume over time (B) and the final
tumor volume (C) are provided. *p < 0.05 by two-way ANOVA to test for dif-
ferences between the curves in (B). The p value for (C) was generated using
Student’s t test with Welch’s correction.
The data are shown as themean ±SEM (B) or SD (C), and for (C), all data points
are shown. See also Figure S4.
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showed that Cx46 is required for GBM CSC proliferative ability,
survival, self-renewal, and tumor formation (Hitomi et al., 2015).
Here, using point mutations that disrupt specific functions of
the protein, we show that the essential function of Cx46 in
these cells is the formation of functional Cx46 GJs. It remains
an open question as to the key tumor cell and CSC mediators
that pass through GJs, which likely include a combination of
ions (K+, Ca2+, and Na+), ROS and antioxidants, metabolites
such as glucose, cyclic AMP (cAMP), and non-coding and
miRNAs (Lim et al., 2011; Loewenstein and Kanno, 1964; Patel
et al., 2016). Our results contrast with the hypothesis that
aberrant hemichannel activity of connexins underlies their role
in pathologies (Kim et al., 2016; Leybaert et al., 2017) and
suggest that therapies designed to target GJIC mediated by
specific connexins may be valuable for certain diseases,
including GBM.
To identify Cx46-specific inhibitors, we screened FDA-
approved compounds for Cx46 GJIC inhibitors and identified
the anti-leprosy drug clofazimine, which inhibited GBM CSC
cell-cell communication; decreased CSC growth, survival, and
self-renewal; and decreased tumor growth in a subcutaneous
tumor model. Although pan-GJ inhibitors are available clinically
and have shown efficacy in our models (Hitomi et al., 2015),
specific inhibitors for connexin isoforms have yet to be identi-
fied or developed. Most connexin modulators developed so
far, the majority of which are designed to target Cx43 or multi-
ple connexin isoforms, are peptide mimetics that interrupt a
specific binding activity of the molecule—either within the
molecule or between molecules—and thus affect protein or
channel function (Jaraı́z-Rodrı́guez et al., 2017; Naus and
Giaume, 2016). Although little is known about precisely how
these mimetics modulate connexin activity, they possess vary-
ing efficiencies at inhibiting and/or stimulating both GJ and
hemichannel activity (Evans et al., 2012; Wang et al., 2013).
However, due to the homology among connexin isoforms,
many of these mimetics fail to exhibit specificity for a specific
connexin. In contrast, we show that the small molecule clofazi-
mine is more specific for Cx46 than Cx43, Cx45, and Cx37.
Few small molecules have been identified to target connexins;
those that have been developed increase GJIC in astrocytes or
specifically target hemichannels, neither of which are relevant
to blocking Cx46-mediated GJIC in GBM CSCs (Naus and
Giaume, 2016).
Previous studies described an inhibitory role for clofazimine in
GBM cells. Significant apoptosis has been observed in conven-
tional GBM cell lines treated with clofazimine, and this cell death
was attributed to inhibition of the mitochondrial membrane ion
channel Kv1.3 (Venturini et al., 2017). We observed similar cell
deathofGBMCSCsupon treatmentwith clofazimine,with little ef-
fect on non-CSCs.However,wealsodetected4-fold higher levels
of Kv1.3 transcript in the clofazimine-resistant non-CSC popula-
tion, suggesting that clofazimine does not act through Kv1.3 inhi-
bition in our hands. Clofaziminewas also previously identified in a
screen to inhibit growth of the conventional GBM cell line U87
(Jiang et al., 2014). In contrast, rather than screening for com-
pounds that inhibit GBM cell growth in culture, we identified a
CSC essential process, Cx46-mediated GJIC, and screened for
inhibitors specifically targeting this cellular process. Our future
work will investigate the mechanism by which clofazimine blocks
Cx46-mediated intercellular communication. Based on our ob-
servations that the cysless mutant inhibits CSC maintenance
similarly to clofazimine and that few transcripts were altered
by short-term treatment, we speculate that the drug could act
extracellularly to physically block the channel opening or hemi-
channel-hemichannel docking. However, it remains possible
that clofazimine functions in another manner, for example, by
altering membrane permeability, mitochondrial function, or cell
signaling.
Although clofazimine shows promise for targeting GBM
CSCs, there are several challenges to its therapeutic use.
Here, we show that clofazimine exhibits minimal penetration
of the blood-brain barrier, and its low solubility and high lipo-
philicity are also barriers to translation for brain tumors. There
has been conflicting evidence for whether clofazimine is able
to penetrate the blood-brain barrier; while some studies have
reported no detectable levels in the brain (Baik et al., 2013;
Holdiness, 1989), other studies detected a level of 156 ng/mL
of clofazimine in the brain of mice treated with 25 mg/kg of
the drug (Baijnath et al., 2015) and an effect on Kv1.3 channels
in the brain of animals treated with clofazimine at 50 mg/kg
after traumatic brain injury (Reeves et al., 2016). In contrast,
using the equivalent of twice the maximum tolerated human
dose (4.88 mg/kg in mice), we detected only 0.55 ng/mL of clo-
fazimine in the brain, a level approximately 2,000-fold lower
than the IC50 value for CSCs, using mass spectrometry. This
difference may be due to differences in concentration, delivery
route, or solvent. In a previous report, clofazimine failed to
inhibit growth of intracranial syngeneic mouse gliomas (Ventur-
ini et al., 2017), which is supported by our observations that
clofazimine at human-relevant doses does not effectively cross
the blood-brain barrier. These challenges would preclude the
direct use of clofazimine to treat patients with brain tumors.
However, future medicinal chemistry derivatization of clofazi-
mine to optimize solubility and blood-brain barrier penetration
may allow us to develop a more optimal analog based on
the clofazimine scaffold for further pre-clinical and clinical
testing. These optimized compounds could lead to improved
next-generation therapies with reduced side effects for patients
with GBM.
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GBM xenograft T3691 Duke University T3691
GBM xenograft T387 Duke University T387
GBM xenograft L2 University of Florida hGBM L2
Chemicals, Peptides, and Recombinant Proteins
Clofazimine Sigma-Aldrich C8895
Geltrex Life Technologies A1413201
FuGENE HD Promega E2311
X-tremeGene HP Roche 6366244001
Vybrant DiD Thermo Fisher V22887
2-NBDG Thermo Fisher N13195
Temozolomide Santa Cruz sc-203292A
H2DCFDA Thermo Fisher D399
Calcein AM Thermo Fisher C3099
Calcein red-orange AM Thermo Fisher C34851
Critical Commercial Assays
CellTiter-Glo Promega G7572
CaspaseGlo 3/7 Promega G8090
Papain Dissociation Kit Worthington Biochemical LK003150
qSCRIPT cDNA Supermix Quanta Biosciences 95048-100
SYBR-Green Mastermix SA Biosciences 330523
Experimental Models: Cell Lines
HeLa cells ATCC CCL-2
NIH 3T3 cells ATCC CRL-1658
Experimental Models: Organisms/Strains
Mouse: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ The Jackson Laboratory 005557
Oligonucleotides
qPCR primer Kv1.3 F: CAAAACGGGCAATTCCACTG This paper N/A
qPCR primer Kv1.3 R: TGAGCACAGCATGTCACTTG This paper N/A
qPCR primer Cx46 F: TGCACAGGAGCACTCCA This paper N/A
qPCR primer Cx46 R: GCGTGGACACGAAGATGAT This paper N/A
Primers for creating Cx46 mutants, see Table S2. This paper
Recombinant DNA
Cx46 cDNA R&D Systems RDC0535
pLPCX-Cx43-IRES-GFP Addgene 65433
pcDNA3.1/Hygro(+)-GJC1 GenScript cloneID: OHu04829
pcDNA3.1/Hygro(+)-GJA4 GenScript cloneID: OHu33346
Cx46 L11S This paper N/A
Cx46 T19M This paper N/A
Cx46 cysless This paper N/A
Software and Algorithms
Extreme limiting-dilution analysis Hu and Smyth, 2009 http://bioinf.wehi.edu.au/software/elda/
GlioVis Bowman et al., 2017 http://gliovis.bioinfo.cnio.es
DAVID Jiao et al., 2012 https://david.ncifcrf.gov/
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CONTACT FOR REAGENT AND RESOURCE SHARING
Requests for reagents should be directed to the Lead Contact, Dr. Justin D. Lathia, at lathiaj@ccf.org.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Origin of Cells
Established GBM xenografts T4121, T3691, and T387 were previously reported (Alvarado et al., 2016; Bao et al., 2006; Schonberg
et al., 2015) and were obtained via a material transfer agreement from Duke University. L2 cells were obtained from the University of
Florida (Deleyrolle et al., 2011; Siebzehnrubl et al., 2013). All humanGBMsamples were originally established under an IRB-approved
protocol that facilitated the generation of xenografts in a de-identified manner from excess tissue taken from consented patients.
GBMcells were passaged in immune-deficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)mice (obtained from The Jackson Laboratory,
Bar Harbor, ME, USA) and dissociated from establishedmouse xenografts under Cleveland Clinic-approved protocols. Six-week-old
female mice were unilaterally injected subcutaneously in the flank with freshly dissociated humanGBMcells, and animals were sacri-
ficed by CO2 asphyxiation and secondary cervical dislocation when tumor volume exceeded 5% of the animal’s body weight. HeLa
and NIH 3T3 cells were obtained from ATCC.
Subcutaneous Tumors
Six- to eight-week-old immunocompromised male or female NSG mice were injected with either 5x105 or 1x106 CSCs from the
patient-derived xenograft T4121 into their right flank as specified in the figure legends. Three to four weeks later, when tumors
were palpable, mice were treated with clofazimine. Clofazimine was solubilized in corn oil, and mice received either 100 mL via intra-
peritoneal injection or 10 mL by intratumoral injection. Tumor dimensionsweremeasured using digital calipers, and tumor volumewas
calculated assuming that the tumors were ellipsoid using the formula: tumor volume = (4/3)p(width/2)2(height/2). Animals were sacri-
ficedwhen they reached endpoint. All animal experiments were performed under Cleveland Clinic-approved Institutional Animal Care
and Use Committee-approved protocols.
Cell Culture
Xenograft tumors were dissociated using papain (Worthington Biochemical Corporation, Lakewood, NJ) and cultured overnight in
supplemented neurobasal medium (neurobasal medium (Life Technologies) with 2% B27 (Life Technologies), 1% penicillin/strepto-
mycin (Life Technologies), 1mMsodium pyruvate (Life Technologies), 2mML-glutamine, 20 ng/mL EGF (R&DSystems,Minneapolis,
MN, USA), and 20 ng/mL FGF-2 (R&D Systems)). T4121, T3691, and T387 xenografts were sorted for CD133+ (CSC) and CD133-
(non-CSC) populations using the CD133 Magnetic Bead Kit for Hematopoietic Cells (CD133/2; Miltenyi Biotech, San Diego, CA,
USA). CD133+ cells were maintained in supplemented neurobasal. CD133- cells were maintained in DMEM with 10% FBS and
1% pen/strep. L2 cells were maintained in these divergent media conditions without sorting.
HeLa and NIH 3T3 cells were maintained in DMEM with 10% FBS and 1% pen/strep. The HeLa-Cx46 stable cell line was cultured
with the addition of 400 mg/mL G418. All cells were grown in a humidified incubator at 37C with 5% CO2.
METHOD DETAILS
Plasmids and DNA Constructs
The Cx46 expression vector was created by inserting the Cx46 cDNA (catalog# RDC0535, R&D Systems) between the HindIII and
XbaI sites of pEGFP-N3, excising the GFP tag. This backbone was used for site-directed mutagenesis to introduce the L11S,
T19M, and cysless mutations, using the primers shown in Table S2. The primers for the cysless mutant were designed so that the
PCR reactions must be performed sequentially from the N-terminus to the C-terminus.
pLPCX-Cx43-IRES-GFP was obtained from Addgene (#65433). pcDNA3.1/Hygro(+)-GJC1 (Cx45; cloneID: OHu04829) and
pcDNA3.1/Hygro(+)-GJA4 (Cx37; cloneID: OHu33346) were obtained from GenScript.
Transfections and Establishment of HeLa-Cx46 Stable Cell Line
For GBM CSC transfections, 1x106 cells were plated per well of a 6-well plate adherently on Geltrex (Thermo Fisher Scientific) to
obtain a confluence of approximately 75%–80%. Six hours later, cells were transfected with Cx46 or its mutant forms using FuGENE
HD (Promega) according to themanufacturer’s protocol. Briefly, cells were transfected with 5 mg total DNA (4 mg of connexin and 1 mg
pEGFP-N3 to track transfection efficiency) using 15 ml FuGENE per well. The following day, cells were removed from the plate using
Accutase (BioLegend) and plated for downstream assays. pEGFP-N3 was used as a vector control.
HeLa cells were seeded at 400,000 cells per well in a 6-well plate and transfected using XtremeGene HP (Roche) according to the
manufacturer’s protocol. In brief, each well received 2 ug of DNA and 6 uL of XtremeGene reagent. Dye-transfer recipients were
plated 24 hours after transfection, and donors were plated and images taken at 48 hours post-transfection. Stable HeLa-Cx46 cells
were derived by transfecting HeLa cells with Cx46 (without the GFP tag). Cells were selected with G418 (400 mg/mL), and single-cell
clones were tested for the ability to exhibit dye coupling.
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Compounds
Clofazimine was obtained from Sigma-Aldrich (catalog # C8895) and solubilized in DMSO at a concentration of 10 mM for in vitro
experiments and in corn oil for in vivo experiments.
Proliferation and Apoptosis
For proliferation, IC50, and apoptosis assays, 2,000 cells were plated in growth media per well of a white-walled 96-well plate in trip-
licate. The number of cells was measured using CellTiter-Glo (Promega) on days 0, 1, 3, 7, and 10 according to the manufacturer’s
protocol, using ATP content as a surrogate of cell number, and apoptosis was measured using CaspaseGlo 3/7 (Promega) on days 1
and 3 according to themanufacturer’s protocol. For the proliferation of GBMCSCs in the presence of Cx46 andCx46mutants, similar
results were obtained using the DNA-based CyQUANT Direct Cell Proliferation Assay Kit (Thermo Fisher Scientific). For drug treat-
ments, cells were seeded in triplicate at 2,000 cells per well of a 96-well plate, and the appropriate concentration of drug was added
6-24 hours later. Cells were analyzed both at 0 and 72 h after treatment with drug.
Limiting Dilution Analysis
CSCswere dissociated using Accutase and plated in a 96-well plate at increasing cell numbers (1, 5, 10, and 20 cells/well) with 24 rep-
licatespercell number.Cellswereplated intodrug-containingmedia, and thenumberofwellscontainingsphereswascountedafter 10-
14days.Anonlinealgorithm (http://bioinf.wehi.edu.au/software/elda/) (HuandSmyth, 2009)wasused tocalculate stemcell frequency.
cDNA and qPCR
For qPCR, RNAwas extracted from cells using TriZOL (Life Technologies) according to themanufacturer’s protocol. A total of 1 mg of
RNAwas used for reverse transcription using a qScript cDNA Synthesis Kit (QuantaBio) according to the manufacturer’s recommen-
dations. Equal volumes of cDNAwere amplified using Fast SYBRGreenMasterMix (Applied Biosystems) on a Step-One Plus Real-
Time PCR system (Applied Biosystems). Data were analyzed using the DDCt method to calculate relative levels of product. qPCR
primers are provided in the Key Resources Table.
Screen of the NIH Clinical Collection for Cx46 Inhibitors
Non-labeled Cx46-HeLa cells were seeded at 20,000 cells per well in a 96-well plate in DMEMwith 10% FBS and 1% pen/strep. The
following morning, drugs were added to a concentration of 10 mM to 80 of the wells, leaving 16 for positive and negative inhibition
controls. CBX (200 mM) was used a positive control for dye transfer inhibition, while negative control wells were left untreated. Sepa-
rately, a population of calcein AM/Vybrant DiD dual-labeled Cx46-HeLa cells was generated. These cells were incubated in serum-
free DMEM containing calcein AM (resuspended in 50 mL of DMSO and used at 1:1000; Thermo Fisher Scientific) and Vybrant DiD
(1:500, Thermo Fisher Scientific) at 37C for 1 h. Following a 3 h incubation of the unlabeled recipients with drug, the dual-labeled
donor population was added at a concentration of 3,000 cells/well. These cells were incubated together at 37C for 5 h and then
imaged. Each plate contained 80 drugs and 16 controls, accounting for 9 experimental runs. Each drug was screened one time
per drug as a cursory screen. Following the identification of possible targets, a secondary screen of a selection of top hits that
were visually verified and readily available was performed at drug concentrations of 10 mM, 1 mM, and 0.1 mM.
For screen quantification, calcein fluorescence was used to create a mask to eliminate any cells left entirely unlabeled and any
background fluorescence. The Vybrant DiD fluorescence image was used to create another binarymask to define DiD-positive donor
cells. These mask images were given values of 0 (no dye present) or 1 (dye present) and then multiplied by the calcein image. ImageJ
particle analysis of the resulting product images provided us with the raw integrated density (RID) of the total calcein dye per imaged
cell. The sum of the particle analysis of the product of the calcein mask and the calcein image gave the total calcein amount, and that
of the product of the DiD mask and the calcein image gave the amount of calcein retained in the donor cells. Percent transfer was
calculated by ((total calcein – retained calcein)x100)/total calcein.
For hemichannel function assessment, labeled populations were generated as described above and seeded at 3,000 cells per well.
Cells were given an hour to adhere and then imaged every 15 minutes for 5 hours. Loss of calcein through hemichannels was quan-
tified as the percent of dye that was lost at 5 h compared to time 0.
For HeLa cells expressing different connexin proteins, cells were prepared and imaged as stated above. Imageswere quantified as
the number of unlabeled cells (recipients) receiving calcein dye per donor cell.
For microinjection of CSCs, subconfluent monolayers of cells plated on Geltrex-coated glass coverslips in 35mmdishes were pre-
treated for 16 h with the indicated concentration of clofazimine in growth media. Cells were then injected with far-red fluorescent IgG
and the fluorescent glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) as described (Hitomi
et al., 2015) and imaged as above. Images were again quantified as the number of unlabeled cells (recipients) receiving calcein dye
per donor cell.
GlioVis Analysis of Connexins in GBM
The Cancer Genome Atlas (TCGA) dataset was interrogated using GlioVis (http://gliovis.bioinfo.cnio.es) (Bowman et al., 2017) for
microarray (Agilent-4502A) and RNA-seq levels of all available connexin genes. Relative levels of non-tumor and GBM tissues
were analyzed, and the fold change is represented as a heatmap.
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RNA Sequencing
T4121 CSCs were treated with clofazimine at 2 mM for 6 hours and lysed for RNA using a Nucleospin RNA isolation kit (Macherey-
Nagel, Duren, Germany). RNA-seq libraries were prepared using10,000 ng of total RNA. Briefly, the protocol included PolyA+ RNA
selection, cDNA synthesis, end repair, A-base addition, and ligation of the Illumina-indexed adapters according to previously pub-
lished methods (Zhang et al., 2012). Total transcriptome libraries were prepared as previously described. Library quality and quantity
weremeasured on an Agilent 2100 Bioanalyzer for product size and concentration. Libraries were also precisely quantified by using a
KAPA Library Quantification kit prior to loading on the sequencer and pooled at equimolar quantities between samples. Single-end
libraries were sequenced with the Illumina HiSeq 2500 (1x5 read length), with sequence coverage up to 20 M total reads.
Single-end transcriptome sequencing reads were aligned to the human reference genome (GRCh37/hg19) using the spliced read
mapper TopHat2 (TopHat 2.0.4) (Kim et al., 2013). Gene expression, as fragments per kilobase of exon per million fragments mapped
(FPKM; normalized measure of gene expression), was calculated using Cufflinks (Trapnell et al., 2012). We considered differential
expression of the gene when the calculated p < 0.01 and there was a 1.5-fold difference (increase or decrease).
The database for annotation, visualization and integrated discovery (DAVID) analysis was used for functional clustering and anno-
tation of differentially expressed genes (https://david.ncifcrf.gov/) (Jiao et al., 2012). DAVID is a web-based online bioinformatics
resource that aims to provide tools for pathway mining and the subsequent functional interpretation of large lists of genes/proteins
using a comprehensive and exhaustive set of knowledge-based libraries. The publication on the DAVID webserver suggests inves-
tigating clusters with an enrichment score R 1.3, while our highest enrichment score was 1.06, suggesting no major disturbance of
any functional pathway/gene ontology group.
Reactive Oxygen Species (ROS)
Tomeasure intracellular ROS, CSCswere concurrently treated with 50 mM temozolomide for 24 h and 1 mMclofazimine for 16 h. Cells
were then collected and incubated with 1 mMH2DCFDA (Life Technologies) for 15 min at 37
C. Cells were then washed twice in PBS,
and the green fluorescent DCF produced was analyzed on a BDFortessa flow cytometer. DAPI exclusion was used to gate for live
cells, and H2O2 was used as a positive control for ROS production.
Blood-Brain Barrier
To assess the permeation of clofazimine into normal brain tissue, mice were intraperitoneally injected with 100 mL of a 25mg/mL sus-
pension of clofazimine in corn oil or vehicle. After 10 minutes of circulation, mice were euthanized, and brains were extracted, snap
frozen in isopentane, and sliced into 20 mm sections. Slides were analyzed using a MVX10 MacroView microscope (Olympus) equip-
ped with an ORCA_Flash4.0 v2 sCMOS fluorescent camera (Hamamatsu). A linear range of standards in the brain was developed
with varying concentrations (16 mg/mg to 2.5 mg/mg).
Mass Spectrometry
Brains from mice treated IP with 2.44 mg/kg and 4.88 mg/kg clofazimine were excised and homogenized in PBS. For mass spec-
trometry, clofazimine was used as the internal standard. Brain homogenate (50 mL) was mixed with 150 mL methanol and then centri-
fuged at 12,000 x g for 10 min. The supernatant (100 mL) was transferred to an HPLC vial. For LC/MS/MS analysis of clofazimine, 2 mL
supernatant was injected into a Shimadzu LCMS-8050 for quantitation of clofazimine. A gradient with a flow rate of 0.3 mL/min was
used to separate clofazimine by reverse-phase chromatography using a Prodigy C18 column (2.13 50mm, 5 mm) fromPhenomenex.
The mobile phases were A (water containing 5 mM ammonium acetate) and B (methanol containing 5 mM ammonium acetate). The
run started with 70% mobile phase B from 0 to 2 min. Solvent B was then increased linearly to 100% B from 2 to 6 min and held at
100% B from 6 to 12 min. The column was finally re-equilibrated with 70% B for 7 min. The HPLC eluent was directly injected into a
triple quadrupole mass spectrometer (Shimadzu LCMS-8050), and the clofazimine was ionized at ESI positive mode, using selected
Reaction monitoring (SRM). The SRM transitions (m/z) were 474 to 432. For data analysis, the software Labsolutions was used to
process the data and obtain the peak areas for clofazimine. The external standard calibration curve was used to calculate the con-
centration of clofazimine in the brain homogenate samples.
Retinal Imaging Procedures
Animal preparation and imaging procedures have been previously described (Bell et al., 2015). Briefly, mice were anesthetized using
an IP injection of sodium pentobarbital (68mg/kg). Mydriasis was induced using a 0.5 mL of 0.5% tropicamide phenylephrinemixture.
Topical anesthesia was induced using 0.5% proparacaine. Cornea hydration and ocular media opacities were minimized using
frequent applications of hydrating drops and topical eye shields (Bell et al., 2014). Following the procedure, eyes were covered
with puralube ointment. Mice recovered in a warmed Plexiglas chamber with supplemental oxygen.
Confocal scanning laser ophthalmoscope (cSLO) imaging was performed using an HRA2 system (Heidelberg Engineering, Inc). A
wide-field objective (55) was used to image the retina with the optic nerve disk centrally located within the image frame. Imaging
modes of infrared reflectance (IR-cSLO) at 800 nm and blue peak autofluorescence (BAF-cSLO) at 488 nm were used to image
the retina and vitreoretinal interface.
Spectral-domain optical coherence tomography was performed following cSLO to examine and compare the in-depth retinal
morphology between treatment groups. Orthogonal B-scans (1000 a-scans/b-scan x 15 frames) were collected through the optic
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disk from the horizontal and vertical meridians. The 15 frames from each meridian were co-registered and averaged using ImageJ
and StackReg and TurboReg Plugins (Schneider et al., 2012; Thévenaz et al., 1998).
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical tests were performed using GraphPad Prism 6.0. Information regarding the numbers of experimental replicates, statis-
tical tests performed, and significance values can be found in the figure legend for each figure panel. p % 0.05 was considered
significant.
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